What’s with the Telix (ASX:TLX) share price yo-yo today?

Telix has received US FDA approval for its cancer imaging tool.

| More on:
Scientists working on a screen in laboratory

Image source: Getty Images

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is all over the place in early trade this morning after the company announced a significant update.

The biotechnology company’s shares opened higher today, peaking at $8.15, before plunging to a low $7.70. At the time of writing, its shares are hovering around their previous closing price of $7.79.

Let’s take a look at what might be impacting the Telix share price today.

What did Telix announce?

In today’s announcement, Telix advised it has received the tick of approval from the US Food and Drug Administration (FDA) for its lead product, Illuccix.

The company has developed Illuccix for the diagnostic imaging of men with prostate cancer. It is the first commercially available product in the United States that provides access to what is known as gallium-68 PSMA-PET imaging.

Telix’s prostate cancer diagnostic tool has been gaining momentum for investors in recent months.

The tool will be used on prostate cancer patients at risk of metastasis and those who have a biochemical recurrence.

Tulane Cancer Centre medical director Dr Oliver Sartor was full of praise for the imaging tool.

This product offers a level of flexibility and accessibility to healthcare professionals we really haven’t seen before in this class of products, and may help us provide better patient experiences as a result.

Telix already has approval from the Therapeutic Good Administration for Illuccix in Australia. And the company is working on market authorisation in Europe and Canada.

Management comment

Commenting on the announcement, Telix CEO and managing director Dr Christian Behrenbruch said:

This heralds a new era of patient and physician access to gallium-based PSMA-PET imaging and marks an important new stage for Telix as we bring our first commercial product to market in the United States.

Improved imaging can provide physicians with the insights to determine the most appropriate treatment pathway and give patients in the US access to a specific and sensitive imaging tool for the detection of prostate cancer throughout the body.

Telix share price snap shot

The Telix share price has blasted ahead by more than 102% in the past 12 months. The company’s shares have also shot up 10.5% in the past month.

The biopharmaceutical company has a market capitalisation of around $2.3 billion based on its current share price.

Should you invest $1,000 in Telix right now?

Before you consider Telix, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Telix wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Nothing to see here, just a storm in a teacup as far as this boy and girl are concerned, sipping tea in their living room.
Healthcare Shares

‘Storm in a teacup’: Why the Imugene share price is lifting 14% today

What did Imugene reveal in its letter to shareholders today?

Read more »

A man flies into the sky over a city building-scape with a rocket jet pack sketched onto his back representing the Imugene share price skyrocketing today
Healthcare Shares

Imugene share price surges 18% to lead the ASX 200 on Thursday

What's behind the meteoric gain for this ASX 200 healthcare stock today?

Read more »

Rising arrow on a blue graph symbolising a rising share price.
Healthcare Shares

Next Science shares defy ASX market slump to surge 8%

Next Science shares are set to finish Thursday's trading session on a high note.

Read more »

Team celebrating corporate success screaming with joy.
Healthcare Shares

How is the Polynovo share price managing to push higher today?

Polynovo shares are defying the broader ASX market on Thursday.

Read more »

An unhappy man in a suit sits at his desk with his arms crossed staring the his laptop screen as the Mesoblast share price falls
Healthcare Shares

Mesoblast share price dips amid latest class action news

The company is being taken to court by another unhappy shareholder.

Read more »

A smiling woman looks at her computer laptop in her home with warm lights in the background feeling happy to see the EMvision share price rising
Healthcare Shares

EMvision share price rockets 11% on $5 million pay day

Shares in the Australian medical device company shot higher today.

Read more »

retirement investing represented by older investor looking concerned at computer screen
Healthcare Shares

Why is the Medibank share price struggling to gain ground in May?

We check what's going on with shares in the private health insurer.

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Healthcare Shares

Here’s why the Imugene share price just got a boost

Imugene's latest announcement is rallying up investors.

Read more »